RXST logo

RxSight Inc. (RXST)

$5.30

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RXST

Market cap

$222224877

EPS

-1.28

P/E ratio

--

Price to sales

1.57

Dividend yield

--

Beta

1.203203

Price on RXST

Previous close

$5.32

Today's open

$5.31

Day's range

$5.18 - $5.43

52 week range

$4.11 - $13.22

Profile about RXST

CEO

Ron Kurtz

Employees

461

Headquarters

Aliso Viejo, CA

Exchange

NASDAQ Global Market

Shares outstanding

41929222

Issue type

Common Stock

RXST industries and sectors

Healthcare

Medical Equipment & Supplies

News on RXST

What RxSight (RXST) Said on Its Q3 Earnings Call

RxSight NASDAQ: RXST reported third-quarter revenue of $24.6 million, down 19% from $30.3 million a year earlier, as the company faced competitive pressure, seasonal effects and disruption tied to a commercial restructuring and sales-force expansion.

news source

MarketBeat • Nov 4, 2026

news preview

RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript

RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

RxSight, Inc. Reports Third Quarter 2026 Results

ALISO VIEJO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 3, 2026

news preview

RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue Estimates

RxSight, Inc. (RXST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.04 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight's common stock to two new non-executive officer employees in connection with the commencement of their employment with RxSight. RxSight also agreed to grant inducement restricted stock units (RSUs) covering a total of 637,449 shares of RxSight's common stock to the same employees in connection with the commencement of their employment with RxSight, which RSUs are anticipated to be granted on or about November 3, 2026.

news source

GlobeNewsWire • Oct 24, 2026

news preview

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

news source

GlobeNewsWire • Oct 20, 2026

news preview

RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation

ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy.

news source

GlobeNewsWire • Oct 19, 2026

news preview

K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world

K2 Vision has performed 5,000+ Light Adjustable Lens procedures and is recognized by RxSight as the highest-volume LAL practice in the world. Learn more.

news source

GlobeNewsWire • Oct 16, 2026

news preview

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.

news source

GlobeNewsWire • Aug 26, 2026

news preview

RxSight Q2 Earnings Call Highlights

RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.

news source

MarketBeat • Aug 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in RxSight Inc.

Open an M1 investment account to buy and sell RxSight Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RXST on M1